158 related articles for article (PubMed ID: 12720140)
1. Prognostic factors and response to fludarabine therapy in Waldenstrom's macroglobulinemia: an update of a US intergroup trial (SW0G S9003).
Dhodapkar MV; Jacobson JL; Gertz MA; Crowley JJ; Barlogie B
Semin Oncol; 2003 Apr; 30(2):220-5. PubMed ID: 12720140
[TBL] [Abstract][Full Text] [Related]
2. Fludarabine therapy in a patient with progressive symptomatic Waldenström's macroglobulinemia.
Hałaburda K; Hellmann A
Acta Haematol Pol; 1994; 25(1):63-7. PubMed ID: 8209618
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine in Waldenstrom's macroglobulinemia.
Leblond V; Choquet S
Semin Oncol; 2003 Apr; 30(2):239-42. PubMed ID: 12720144
[TBL] [Abstract][Full Text] [Related]
4. Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Kyle RA; Treon SP; Alexanian R; Barlogie B; Björkholm M; Dhodapkar M; Lister TA; Merlini G; Morel P; Stone M; Branagan AR; Leblond V
Semin Oncol; 2003 Apr; 30(2):116-20. PubMed ID: 12720119
[TBL] [Abstract][Full Text] [Related]
5. Fludarabine combination therapy is highly effective in first-line and salvage treatment of patients with Waldenström's macroglobulinemia.
Tam CS; Wolf MM; Westerman D; Januszewicz EH; Prince HM; Seymour JF
Clin Lymphoma Myeloma; 2005 Sep; 6(2):136-9. PubMed ID: 16231852
[TBL] [Abstract][Full Text] [Related]
6. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).
Dhodapkar MV; Jacobson JL; Gertz MA; Rivkin SE; Roodman GD; Tuscano JM; Shurafa M; Kyle RA; Crowley JJ; Barlogie B
Blood; 2001 Jul; 98(1):41-8. PubMed ID: 11418461
[TBL] [Abstract][Full Text] [Related]
7. Fludarabine in Waldenstrom's macroglobulinemia.
Souchet-Compain L; Nguyen S; Choquet S; Leblond V
Expert Rev Hematol; 2013 Jun; 6(3):229-37. PubMed ID: 23782076
[TBL] [Abstract][Full Text] [Related]
8. 2-Chlorodeoxyadenosine alone and in combination for previously untreated Waldenstrom's macroglobulinemia.
Weber DM; Dimopoulos MA; Delasalle K; Rankin K; Gavino M; Alexanian R
Semin Oncol; 2003 Apr; 30(2):243-7. PubMed ID: 12720145
[TBL] [Abstract][Full Text] [Related]
9. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
Leblond V; Johnson S; Chevret S; Copplestone A; Rule S; Tournilhac O; Seymour JF; Patmore RD; Wright D; Morel P; Dilhuydy MS; Willoughby S; Dartigeas C; Malphettes M; Royer B; Ewings M; Pratt G; Lejeune J; Nguyen-Khac F; Choquet S; Owen RG
J Clin Oncol; 2013 Jan; 31(3):301-7. PubMed ID: 23233721
[TBL] [Abstract][Full Text] [Related]
10. Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia.
Del Giudice I; Matutes E; Osuji N; Parry-Jones N; Swansbury J; Catovsky D
Haematologica; 2005 Feb; 90(2):268-70. PubMed ID: 15710588
[TBL] [Abstract][Full Text] [Related]
11. Appropriateness of applying the response criteria for multiple myeloma to Waldenstrom's macroglobulinemia?
Bladé J; Montoto S; Rosiñol L; Montserrat E
Semin Oncol; 2003 Apr; 30(2):329-31. PubMed ID: 12720163
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors in symptomatic Waldenstrom's macroglobulinemia.
Merlini G; Baldini L; Broglia C; Comelli M; Goldaniga M; Palladini G; Deliliers GL; Gobbi PG
Semin Oncol; 2003 Apr; 30(2):211-5. PubMed ID: 12720138
[TBL] [Abstract][Full Text] [Related]
13. Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease.
Cesana C; Miqueleiz S; Bernuzzi P; Tresoldi E; Rossi V; D'avanzo G; Filippini D; Morra E
Semin Oncol; 2003 Apr; 30(2):231-5. PubMed ID: 12720142
[TBL] [Abstract][Full Text] [Related]
14. Waldenström's macroglobulinemia.
Dimopoulos MA; Anagnostopoulos A
Best Pract Res Clin Haematol; 2005; 18(4):747-65. PubMed ID: 16026748
[TBL] [Abstract][Full Text] [Related]
15. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Waldenstrom's macroglobulinemia with nucleoside analogues.
Dimopoulos MA; O'Brien S; Kantarjian H; Estey EE; Keating MJ; Alexanian R
Leuk Lymphoma; 1993; 11 Suppl 2():105-8. PubMed ID: 7907250
[TBL] [Abstract][Full Text] [Related]
17. Advanced Waldenström's macroglobulinemia: usefulness of Morel's scoring system in establishing prognosis.
Lévy V; Morel P; Porcher R; Chevret S; Wattel E; Leblond V
Haematologica; 2005 Feb; 90(2):279-81. PubMed ID: 15710594
[TBL] [Abstract][Full Text] [Related]
18. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients.
Tamburini J; Lévy V; Chaleteix C; Fermand JP; Delmer A; Stalniewicz L; Morel P; Dreyfus F; Grange MJ; Christian B; Choquet S; Leblond V
Leukemia; 2005 Oct; 19(10):1831-4. PubMed ID: 16121217
[TBL] [Abstract][Full Text] [Related]
20. An unusual reoccurrence of Waldenstrom's macroglobulinemia as pleural effusions that had a discordant response with treatment.
Amin CJ; Rabinowitz I
Clin Lab Haematol; 2005 Jun; 27(3):200-2. PubMed ID: 15938727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]